封面
市场调查报告书
商品编码
1084692

肝素市场:规模,占有率,预测,机会分析(2022年~2028年)

Heparin Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日期: | 出版商: Coherent Market Insights | 英文 149 Pages | 商品交期: 2-3个工作天内

价格
简介目录

冠状动脉疾病,肺动脉栓塞,深部静脉血栓症等的疾病增加,成为肝素需求增加的主要原因之一。

本报告提供全球肝素市场相关调查,市场概要,以及各产品类型,各剂型,各地区的趋势,及加入此市场的主要企业简介等资讯。

目录

第1章 调查目的、前提条件

第2章 市场概要

  • 报告的说明
  • 摘要整理
    • 市场明细:各产品类型
    • 市场明细:各剂型
    • 市场明细:各地区
  • Coherent Opportunity Map(COM)

第3章 市场动态,法规,及趋势分析

  • 概要
  • 市场动态
    • 促进因素
    • 阻碍因素
    • 市场机会
  • 影响分析
  • 市场趋势
  • 主要的发展
  • 开发平台分析
  • 供应链分析
  • 法规情形
  • 流行病学分析

第4章 全球肝素市场:各产品类型,2017年~2028年,(100万美元)

  • 简介
  • 未分级肝素(UH)
  • 低分子量肝素(LMWH)
  • 超低分子量肝素(ULMW)

第5章 全球肝素市场:各剂型,2017年~2028年,(100万美元)

  • 简介
  • 注射
  • 溶剂

第6章 全球肝素市场:各地区,2017年~2028年,(100万美元)

  • 简介
  • 北美
  • 欧洲
  • 亚太地区
  • 南美
  • 非洲
  • 中东

第7章 竞争情形

  • 热图分析
  • 企业简介
    • Anselm Pharmaceuticals
    • Baxter International Inc.
    • B. Braun Melsungen AG
    • Bristol-Myers Squibb Co.
    • Dr. Reddy's Laboratories Ltd.
    • Fresenius SE &Co. KGaA
    • Leap Labchem Co.
    • LEO Pharma A/S
    • Pfizer, Inc.
    • Sanofi SA
    • Syntex SA
    • Teva Pharmaceutical Industries Ltd.
    • United Biotech(P)Ltd.
  • 分析师的见解

第8章 Section

简介目录
Product Code: CMI2602

Heparin is an anticoagulant used to decrease the clotting ability of blood and help to prevent harmful clots from forming in blood vessels. It is sometimes referred as a blood thinner, although it does not actually thin the blood. Heparin does not dissolve already formed blood clots, but it can prevent the clots from becoming larger and causing more serious problems. Pharmaceutical-grade heparin is derived from animal tissue. Heparin is commonly used in the treatment of coronary heart disease, pulmonary embolism, deep vein thrombosis, and atrial fibrillation, and in the prevention of thrombosis during extracorporeal membrane oxygenation and cardiopulmonary bypass.

Market Dynamics

Rising cases of conditions such as coronary heart disease, pulmonary embolism, and deep vein thrombosis is one of the major factors for increased demand of heparin drugs in the market. Myocardial infarction (MI) is one of the major complications of coronary heart disease. According to the American Heart Association 2018 report, coronary heart disease is the leading cause (43.8%) of deaths due to cardiovascular disease in the U.S., followed by stroke (16.8%). As per the Centres for Disease Control and Prevention (CDC) 2015 report, deep vein thrombosis affects nearly 900,000 individuals in the U.S. each year.

Despite major applications in chronic conditions, heparin is poorly absorbed by the intestine, therefore it must be given intravenously or subcutaneously. Moreover, the drug creates a significant risk of excessive bleeding due to anticlotting effect. Heparin also induce conditions such as thrombocytopenia (reduced number of circulating platelets) and hypersensitivity reactions. These factors can hamper the heparin market, during the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the heparin market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global heparin market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Anselm Pharmaceuticals, Baxter International Inc., B. Braun Melsungen AG, Bristol-Myers Squibb Co., Dr. Reddy's Laboratories Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., LEO Pharma A/S, Pfizer, Inc., Sanofi S.A., Syntex S.A., Teva Pharmaceutical Industries Ltd., and United Biotech (P) Ltd.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global heparin market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for heparin market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Heparin Market, By Product Type:
    • Unfractionated Heparin (UH)
    • Low Molecular Weight Heparin (LMWH)
    • Ultra-low Molecular Weight Heparin (ULMW)
  • Global Heparin Market, By Dosage Form:
    • Injection
    • Solutions
  • Global Heparin Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Product Type:
    • Unfractionated Heparin (UH)
    • Low Molecular Weight Heparin (LMWH)
    • Ultra-low Molecular Weight Heparin (ULMW)
      • By Dosage Form:
    • Injection
    • Solutions
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Product Type:
    • Unfractionated Heparin (UH)
    • Low Molecular Weight Heparin (LMWH)
    • Ultra-low Molecular Weight Heparin (ULMW)
      • By Dosage Form:
    • Injection
    • Solutions
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Product Type:
    • Unfractionated Heparin (UH)
    • Low Molecular Weight Heparin (LMWH)
    • Ultra-low Molecular Weight Heparin (ULMW)
      • By Dosage Form:
    • Injection
    • Solutions
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Product Type:
    • Unfractionated Heparin (UH)
    • Low Molecular Weight Heparin (LMWH)
    • Ultra-low Molecular Weight Heparin (ULMW)
      • By Dosage Form:
    • Injection
    • Solutions
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Product Type:
    • Unfractionated Heparin (UH)
    • Low Molecular Weight Heparin (LMWH)
    • Ultra-low Molecular Weight Heparin (ULMW)
      • By Dosage Form:
    • Injection
    • Solutions
    • Africa
      • By Country:
    • South Africa
    • Central Africa
    • North Africa
      • By Product Type:
    • Unfractionated Heparin (UH)
    • Low Molecular Weight Heparin (LMWH)
    • Ultra-low Molecular Weight Heparin (ULMW)
      • By Dosage Form:
    • Injection
    • Solutions
  • Company Profiles
    • Anselm Pharmaceuticals*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Baxter International Inc.
    • B. Braun Melsungen AG
    • Bristol-Myers Squibb Co.
    • Dr. Reddy's Laboratories Ltd.
    • Fresenius SE & Co. KGaA
    • Leap Labchem Co.
    • LEO Pharma A/S
    • Pfizer, Inc.
    • Sanofi S.A.
    • Syntex S.A.
    • Teva Pharmaceutical Industries Ltd.
    • United Biotech (P) Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Product Type
    • Market Snippet, By Dosage Form
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Overview
  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Pipeline Analysis
  • Supply Chain Analysis
  • Regulatory Landscape
  • Epidemiology Analysis

4. Global Heparin Market, By Product Type, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Unfractionated Heparin (UH)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Low Molecular Weight Heparin (LMWH)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Ultra-low Molecular Weight Heparin (ULMW)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

5. Global Heparin Market, By Dosage Form, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Injection
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Solution
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Heparin Market, By Region, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2028
    • Regional Trends
  • North America
    • Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Dosage Form, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Dosage Form, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Dosage Form, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Dosage Form, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Dosage Form, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • Northern Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Dosage Form, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • GCC Countries
    • Israel
    • Rest of Middle East

7. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Anselm Pharmaceuticals
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Baxter International Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • B. Braun Melsungen AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Bristol-Myers Squibb Co.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Dr. Reddy's Laboratories Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Fresenius SE & Co. KGaA
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Leap Labchem Co.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • LEO Pharma A/S
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Sanofi S.A.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Syntex S.A.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • United Biotech (P) Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Analyst Views

8. Section

  • References
  • Research Methodology
  • About Us and Sales Contact